Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
← Back to archive
2022 Michigan Negative

Neg - Biotech Updates - Michigan 7 2022 FMPS

Neg - Biotech Updates - Michigan 7 2022 FMPS.docx

Download Word file
Indexed text preview
Biotech Neg 2 - FMPS
Disad things
CP – Bioethics Commission
1NC
USFG should establish a bioethics commission
A reestablished bioethics commission solves dual use – establishes public-private partnerships that create norms, pressure and incentives check bad actors
1AC Fox '22 - Professor of Law, Herzog Endowed Scholar, and Director of the Center for Health Law Policy & Bioethics at the University of San Diego School of Law [Dov, Apr 25, "The Biotech Battlefield How to Contend With China’s Risky R&D," https://www.foreignaffairs.com/articles/china/2022-04-25/biotech-battlefield]
PLAYING WITH FIRE
Morally fraught experiments have flourished in China in recent years. In 2017, surgeons at Harbin Medical University defied international condemnation to attempt the first human head transplant. In 2018, a Shenzhen biophysicist implanted embryos edited through experiments that risked introducing destructive mutations into the human gene pool. And in 2019, China’s Institute of Zoology invited a Spanish biochemist to create human-monkey chimeras as organ transplant sources.
These boundary-pushing developments aren’t just the work of a few bad apples. Rogue scientists are the predictable product of a national system that reduces research oversight in Beijing to a “rubber stamp,” according to recent testimony before the World Health Organization by the Chinese medical ethicist Hu Qingli. Indifference is part of the problem. The Chinese Ministry of Health, for instance, ostensibly banned unauthorized stem cell therapies in 2012. But a decade later, pop-up stem cell clinics still hawk untested interventions to repair spinal cords and augment breasts. Corruption is another factor. Incidents of bribery at the China Food and Drug Administration, now known as the National Medical Products Administration, led to mass casualties from at least six tainted drugs meant to treat autoimmune disorders, erectile dysfunction, and other ailments.
Then there is China’s heavy-handed program of biometric surveillance and population control. In 2018, Beijing used Islamic terrorism as a pretext to launch the most technologically sophisticated regime of data mining and collection that the world has ever seen. Drones with facial recognition cameras hover over regions such as Xinjiang while police at checkpoints take mandatory iris scans, blood samples, and genetic tests from Uyghur Muslims. Beijing exports this digital security and mass surveillance architecture to dozens of other countries, including Egypt and Uganda, where they have been used to persecute sexual minorities and religious dissidents.
Even countries that use these tools to promote public health and safety unwittingly supply China with their citizens’ biometric information. According to a Reuters investigation, Shenzhen-based BGI Genomics is amassing and analyzing genetic data on women and fetuses from a noninvasive prenatal test that the firm developed in conjunction with the Chinese military. The kit is marketed in more than 50 countries, including Australia, Canada, Denmark, Germany, India, Pakistan, Spain, Thailand, and the United Kingdom. Roughly 8.4 million women have used it. One BGI study allegedly used a military supercomputer to “map the prevalence of viruses in Chinese women, look for indicators of mental illness in them, and single out Tibetan and Uyghur minorities to find links between their genes and their characteristics.”
China’s top-down approach to biotechnology also has serious implications for family planning. The country’s now lapsed one-child policy was supposed to bring economic prosperity. Instead, it yielded an epidemic of forced sterilizations, abortions, and female infanticide that produced the country’s current lopsided sex ratio and aging workforce. But that experience hasn’t stopped Beijing from experimenting with new forms of genetic control. A 1995 law aimed at “avoid[ing] new births of inferior quality and heighten[ing] the standards of the whole population” requires couples at risk of passing along infectious or hereditary diseases to use long-term contraceptives or postpone marriage until after child-bearing age.
In 2022, moreover, millions of Chinese parents will use state-subsidized “talent tests” to screen offspring for traits such as height, intelligence, memory, extroversion, musical ability, and athletic prowess. These policies of biological selection and enhancement extend beyond family planning. A 2016 Chinese government report, for instance, underscored the potential value of gene editing to boost troops’ combat effectiveness. Former U.S. Director of National Intelligence John Ratcliffe warned in a recent Wall Street Journal op-ed that the Chinese military is working to engineer “soldiers with biologically enhanced capabilities”—from superstrength to altitude sickness resistance.
INNOVATE OR PERISH
Chinese developments in biotechnology demand a U.S. response.the last national bioethics commission lapsed in 2017, and Washington has yet to authorize a replacement. A newly established commission should engage with universities and industries to set norms and expectations around bioethics. Good models for this kind of public-private collaboration already exist. Organizations such as the Secure DNA Project and the Morningside Group—independent coalitions dedicated to safely and fairly governing genetic synthesis and brain-computer interfaces, respectively—are examples of what scientists, ethicists, and others can accomplish together. Future interdisciplinary teams can act as gatekeepers to affirm moral standards and condemn transgressions—for instance, by determining who gets published in high-impact journals and invited to prestigious conferences.
These partnerships can also help bridge ideological differences on issues such as vaccine passports, gene-edited immunity, and challenge trials that pay people to test new therapies for COVID-19. These are debates that democratic societies are well equipped to handle. Four of the world’s biggest democracies—Australia, India, Japan, and the United States—have recognized the existential stakes of life sciences research and recently pledged to collectively tackle “the critical and emerging technologies of the future, beginning with biotechnology.” That work should include establishing a global medical ethics consortium built on international agreements such as the Universal Declaration on Bioethics and Human Rights, treaties such as the Biological Weapons Convention, and multilateral arrangements such as the T-12—a group of technologically advanced democracies.
Still, democratic societies can’t maintain bioethical standards alone. Going forward, the United States and other democracies must engage with authoritarian states, especially on areas of shared interest, including biodiversity, climate change, and highly infectious diseases. A natural starting point is oversight to ensure that Beijing actually implements its Biosecurity Law of 2021—legislation designed to guide Beijing’s policies on everything from bioterrorism to biotechnology. Washington should also focus on developing new treaty guidelines for human experimentation and genetic-information sharing.
THE OLYMPIC SPIRIT
China’s DNA-based approach to picking its 2022 Olympic competitors may look like a harbinger of a grim future. But the country’s athletic history also suggests a path for managing this new form of geopolitical competition.
Between 1988 and 1998, 52 Chinese Olympic athletes tested positive for banned performance-enhancing drugs, including a half dozen gold medal winners. In response to the resulting international outcry, the International Olympic Committee created the World Anti-Doping Agency. Chastened, China developed the world’s most rigorous anti-doping measures—mandating education, exams, and pledges among athletes and coaches. Violators got lifetime bans. The Chinese state also sought to repair its reputation, funding new research and pledging long-term commitments to international anti-doping efforts.
At the time, verification and transparency made it possible to hold China accountable for its ethics violations, and international pressure and the threat of meaningful sanctions drove Beijing to act more responsibly—in sports, anyway. Similar policies could work today in the field of bioethics, helping rein in China’s reckless behavior. In this way, Beijing’s revolutionary Olympic selection process could be the opening the world needs to thrash out the moral status of scientific advances just over the horizon.
A commission on bioethics solves dual use – guidelines, research, and framework for development
Childress 17 – professor of ethics at the University of Virginia, founder of the Insitute for Practical Ethics and Public life, author of books and articles in bioethics, served on the National Bioethics Advisory Commission until 2001 [James F. “The Bioethical Approach: The President should establish a commission on bioethics.” UVA Miller Center for Public Policy. May 9, 2017]
In his first year, President Donald Trump should develop a charter for, assign priorities to, and establish by executive order a new presidential commission on bioethics. Even though its membership should be diverse in background, experience, and expertise, it is reasonable for the president to set up a commission that is generally congenial to his administration’s values. The commission’s main function will be to provide advice and counsel to the president. It can also report directly to federal departments and agencies and to congressional committees. Further, its meetings and reports can contribute to public discourse and education about bioethics.
Doing so will build on the best practices of previous presidents, who have used such outside guidance to address complex ethical challenges in the biological sciences, medicine, and health care. The new president can choose from several options in how to design such a commission, and which topics to address. But having such a commission will ensure that thoughtful examination will guide emerging technologies.
Public bioethics is . . . vitally important.
While bioethics, a term coined in 1970, has various meanings, a primary definition features ethical reflection and judgment regarding the biological sciences, medicine, and health care. Bioethical reflection and judgment often focus directly on such activities as clinical care, but public bioethics is also vitally important. It focuses on public policies, many of which fall under the auspices of the executive branch, particularly the office of the president of the United States, who may direct departments and agencies to consider and develop policies on bioethical topics. Many of these initiatives will also involve interactions with Congress and the courts. In addition to public policies, the president may also have a significant impact on public discourse and education in bioethics, which may in turn shape public policies.
Sign warning of ebola virus
In the event of a public health crisis such as a Ebola pandemic, the president should develop ethically acceptable public health policies and practices.
The president’s priorities should include ensuring the retention and implementation of recently updated rules and guidelines for protecting human research participants and, at the same time, facilitating important research; developing a framework for ethically acceptable public health policies and practices in the event of public health crises such as pandemics of Ebola and the Zika virus; and moving forward the still evolving societal and public policy discussion about human gene editing. Each of these subjects involves questions about how best to protect individual liberties while promoting the common good. In addition, other emergent ethical problems, occasioned by scientific and technological breakthroughs, can be helpfully addressed by a presidential bioethics commission just as the advent of human cloning, human embryonic stem cell research, and synthetic biology required the attention of one or more of the last three commissions.
Commission solves public bioethics – interdisciplinary review, targeted expertise, and recommendations
Childress 17 – professor of ethics at the University of Virginia, founder of the Institute for Practical Ethics and Public life, author of books and articles in bioethics, served on the National Bioethics Advisory Commission until 2001 [James F. “The Bioethical Approach: The President should establish a commission on bioethics.” UVA Miller Center for Public Policy. May 9, 2017]
Presidential commission on bioethics
Many presidential actions have implications for bioethical controversies. For instance, Trump’s nomination of federal appellate judge Neil Gorsuch for appointment to the U.S. Supreme Court has implications for such “hot button” bioethical issues as abortion and religious liberties not to provide contraception. Several presidential actions in public bioethics, particularly under the circumstances previously noted, can benefit from a systematic and sustained examination by an interdisciplinary body. For most of the last 40 or so years presidential (or congressional) commissions have shouldered much of this task.
Commission meeting
There are three main types of institutional structures for public bioethics: a standing national commission, a series of commissions, or funding nongovernmental committees.
There are three main types of institutional structures for public bioethics, each with distinct advantages and disadvantages. The first is a standing national commission, with a broad mandate and the opportunity to identify specific areas for attention as well as to respond to presidential requests. A second is a series of commissions with mandates that are more focused, targeted, and limited, having to do with particular subjects, such as organ transplantation, human fetal tissue transplantation research, or human embryo research. A major advantage of a standing commission over a series of subject-limited commissions is that it has time to mature as a deliberative body, to develop practices of collective analysis and reasoning, to be prepared for new challenges, and so forth. A major advantage of a targeted, focused commission is that its members can be selected on the basis of their potential contributions to the specific task at hand, which the committee can pursue with concentrated attention and effort. However, it will still take some time to get each ad hoc committee up and running.
A third possibility is to fund nongovernmental committees to produce reports and make recommendations for the president and other governmental bodies. The specific studies undertaken by committees established by the National Academies of Science, Engineering, and Medicine provide one such model. Often established in response to requests and with support from federal departments or agencies such as the Food and Drug Administration (FDA) or the National Institutes of Health (NIH), these independent committees prepare consensus reports, often on single issues such as, recently, novel techniques for prevention of maternal transmission of mitochondrial DNA diseases. Such committees may appear to be less “political” than a presidential or a congressional commission. However, they have a distinct disadvantage: even though they may include public members as well as experts, their process of developing findings, conclusions, and recommendations is not as open as that of governmental bioethics commissions. They may appear more objective and impartial, but they are less publically transparent.
A bioethics commission shapes governmental policy on biotech – solves a laundry list ethical problems – human testing, gene editing, public health
Childress 17 – professor of ethics at the University of Virginia, founder of the Institute for Practical Ethics and Public life, author of books and articles in bioethics, served on the National Bioethics Advisory Commission until 2001 [James F. “The Bioethical Approach: The President should establish a commission on bioethics.” UVA Miller Center for Public Policy. May 9, 2017]
After Dolly the cloned sheep was born, President Bill Clinton asked the National Bioethics Advisory Commission to prepare a report recommending federal policies on human reproductive cloning.
Each of these three institutional mechanisms can contribute significantly to presidential and other governmental bioethical policy making. Which one is best for a particular topic depends in part on process values such as transparency and efficiency. While not every bioethical topic needs to be addressed by a standing presidential bioethics commission, such a commission has the substantial advantage of being able to address a range of bioethical topics, sometimes interrelated, in public over time and the advantage also of being ready to address fairly quickly new issues when they emerge. For instance, following the announcement of the cloned sheep Dolly’s birth, President Bill Clinton gave his relatively young National Bioethics Advisory Commission 90 days to prepare a report recommending possible federal policies toward human reproductive cloning.
Setting priorities for public bioethics
At this point there are several bioethical topics that the new president—and in some cases a new presidential bioethics commission—should take under advisement. Of the three noted below, one (human gene editing) will require special attention because it unsettles long-dominant bioethical and public policy paradigms.
Research involving human subjects or participants
One of the central areas of public bioethics is research involving human “subjects,” now increasingly called “participants” to emphasize that these individuals collaborate with researchers on behalf of the society and that their (or their surrogate’s) voluntary, informed consent is indispensable. Research involving human participants was the focus of the very first commission, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1974–78), which was established in response to several scandals in biomedical research. The most notorious scandal was the U.S. Public Health Service’s research for over 40 years on the effects of untreated syphilis on close to 400 African American males in and around Tuskegee, Alabama. The commission’s work led to new regulations to govern federally funded research (and much other research). Other subsequent commissions have reexamined these rules, in part because research involving human participants has changed so much in volume, the number of institutions and researchers involved, international scope, the nature of the research (e.g., involving genetic information), complexity, etc. Now, after several decades, some of the extant rules may underprotect while others overprotect human participants and some make it difficult or burdensome to conduct needed research.
On January 19, 2017, the newly revised Common Rule—the set of federal regulations for ethically conducting research involving human subjects—was published in the Federal Register, following discussions that had germinated since its original enactment in 1991, deliberations that started in earnest in 2011, and broad input throughout the extended process of rulemaking. The new rule, which is scheduled to take effect in 2018, might appear, at first glance, to be a good target for revocation given the new administration’s commitment to extensive deregulation. However, this revision of a long-established rule is designed to facilitate valuable research, in part by reducing unnecessary regulatory burdens, for instance, by generally requiring a single Institutional Review Board review in multi-institutional studies and by standing against the needlessly long and complex consent forms. At the same time, it is designed to better protect the rights and welfare of research participants. It wou

Preview shortened. Download the file for the full document.